Consensus on the monitoring, treatment, and prevention of leukaemia relapse after allogeneic haematopoietic stem cell transplantation in China: 2024 update

Y Wang, YJ Chang, J Chen, M Han, JD Hu, J Hu… - Cancer Letters, 2024 - Elsevier
The consensus in 2018 from The Chinese Society of Haematology (CSH) on the monitoring,
treatment, and prevention of leukaemia relapse after allogeneic haematopoietic stem cell …

Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best …

DP McLornan, JC Hernandez-Boluda, T Czerw… - Leukemia, 2021 - nature.com
Allogeneic haematopoietic cell transplantation (allo-HCT) remains the only curative
approach in myelofibrosis (MF). Despite advances over recent decades, relapse and non …

[HTML][HTML] Prevention and treatment of acute myeloid leukemia relapse after hematopoietic stem cell transplantation: the state of the art and future perspectives

S Leotta, A Condorelli, R Sciortino, GA Milone… - Journal of Clinical …, 2022 - mdpi.com
Allogeneic hematopoietic stem cell transplantation (HSCT) for high-risk acute myeloid
leukemia (AML) represents the only curative option. Progress has been made in the last two …

[HTML][HTML] Hematopoietic cell transplantation in the treatment of newly diagnosed adult acute myeloid leukemia: an evidence-based review from the American Society of …

B Dholaria, BN Savani, BK Hamilton, B Oran… - … and Cellular Therapy, 2021 - Elsevier
The role of hematopoietic cell transplantation (HCT) in the management of newly diagnosed
adult acute myeloid leukemia (AML) is reviewed and critically evaluated in this evidence …

A practical guide to chimerism analysis: review of the literature and testing practices worldwide

AG Blouin, F Ye, J Williams, M Askar - Human immunology, 2021 - Elsevier
Abstract Background and Purpose Currently there are no widely accepted guidelines for
chimerism analysis testing in hematopoietic cell transplantation (HCT) patients. The …

[HTML][HTML] The role of allogeneic hematopoietic stem cell transplantation in pediatric leukemia

M Algeri, P Merli, F Locatelli, D Pagliara - Journal of clinical medicine, 2021 - mdpi.com
Allogeneic hematopoietic stem cell transplantation (HSCT) offers potentially curative
treatment for many children with high-risk or relapsed acute leukemia (AL), thanks to the …

How I treat high-risk acute myeloid leukemia using preemptive adoptive cellular immunotherapy

A Biederstädt, K Rezvani - Blood, 2023 - ashpublications.org
Allogeneic hematopoietic stem cell transplantation (alloHSCT) is a potentially curative
treatment for patients with high-risk acute leukemias, but unfortunately disease recurrence …

Donor lymphocyte infusions after haploidentical stem cell transplantation with PTCY: A study on behalf of the EBMT cellular therapy & immunobiology working party

N Santoro, JE Mooyaart, R Devillier, Y Koc… - Bone Marrow …, 2023 - nature.com
Donor lymphocyte infusion (DLI) is a treatment option to prevent or treat relapse after
allogeneic hematopoietic cell transplantation (HCT). We here report data for 173 patients …

Optimization of donor lymphocyte infusion for AML relapse after allo-HCT in the era of new drugs and cell engineering

Y Ye, L Yang, X Yuan, H Huang, Y Luo - Frontiers in oncology, 2022 - frontiersin.org
Donor lymphocyte infusion (DLI) is a key strategy for the treatment of AML relapse after
allogeneic hematopoietic cell transplantation (allo-HCT) and has been used for either …

[HTML][HTML] Outcomes of unmanipulated haploidentical transplantation using post-transplant cyclophosphamide (PT-Cy) in pediatric patients with acute lymphoblastic …

A Ruggeri, JE Galimard, O Paina, F Fagioli… - … and Cellular Therapy, 2021 - Elsevier
ABSTRACT HLA-haploidentical transplantation (haplo-HCT) using post-transplantation-
cyclophosphamide (PT-Cy) is a feasible procedure in children with malignancies. However …